Member Info for AVCT

Https://t.co/8hfffxhbcz

"To save me a bit of work AVCT show us the reason the rns was incorrect and avacta have lied"

Do the work CJ I could do with a good laugh

We know you won't

I understand it fine thanks PL

Show us you're numbers so we can see how well you understand

Of course you won't but we knew that

“c.£32.5m cash-in-hand at end-June 2024 stage, together with expected net proceeds from disposal of the Diagnostics division (for which credible indicative offers have already started to be received with further bids anticipated), should provide sufficient runway to complete AVA6000’s Ph.2 study along with development of pre|CISION™’s next generation programmes.”

Not true - but not a problem either

"What maths do you need @AVCT?

Just because you pay 30 odd million for something it doesn't mean it's worth that to someone else. He over paid for them, with our super Broker by his side who knew he'd have to finance it and get they would get their 5pc.

That's not rocket science, but it looks like from where you look...it probably is.

It's going to be under 20m. It would be great if it were more, but I think not. Just a realist."

I'm good thanks - thanks for asking

"@AVCT, do you know for sure that the bulk of Phase 2 will take place in the US?"

Doesn't matter because some of us can convert between £ and $ - you should try it sometime

Btw give CJ a nudge and get him to answer the question - thats if his maths is up to it.

"DX is not going to be 25m even on the best day - I don't think it will start with a 2"

My guess is it starts with a 2

"My point being if DX is sold for £25 m we are fully funded for P2 unless of course it takes 3 years .

100 x £250 k is £25 m my bad BV"

Whats your projection for cash @ March 25 ex DX proceeds CJ ?

How long would you expect P2 to last ?

Btw the use $US in america where the bulk of P2 will take place

I think you'll find it's actually $25m CJ - try reading my post

If you have a point please state it

I think we will be ready to start P2 in mid 2025 so a time of choosing after that and funding

My guess a slim trial something of the order of 100 patients over 12-18 months give or take direct costs $250k each

Cj

6000 P2 funding for STS or SG needs funding in full before it starts

Sience day is 2pm -5 I believe

And recorded video shared afterwards so tommorrow evening at earlist

It'll be a long wait since reportedly he's already been turned down

Can anyone explain why Manopor are a comparator for Avacta - by licencing in a late stage drug, they have done the exact opposite of what we are seeking to do ?

Define "huge"

No idea what the DX sale procceds will be used for.

I'm sure though that BOD will tell us at some point after they have the cash in hand.

"Maybe they're adding in DX profitability?"

Gotta like a man with a sense of humour!

@WAG

Ps I'm not worried as I know the Board are on it and I trust CC and SC to know what they're doing

All our speculation as to how is just guessing as we have a very incomplete picture of all the options open to CC

@WAG

I did note that at the time - but didn't really see how they arrived at that inclusion, other than as a result of future events now being set in motion, such as sale DX for one.

My estimate of cash @ end September was £23m give or take and next march something like £13m absent any other events.

Would love to know how that lasts to end 2025, let alone March 2026

I think we wanted TNBC as well but can't announce anything until we have a route to that in place.

Note how the p1b inclusion wasn't actually in the RNS release - just sneaked into the public domain on a pipeline update page without commentary.